Home | Welcome to Contract Pharma   
Last Updated Friday, August 1 2014
Print

Financial Report: Bristol-Myers Squibb



Published January 24, 2013
Bristol-Myers Squibb
 
4Q Revenues: $4.2 billion (-23%)

4Q Earnings: $924 million (-25%)

YTD Revenues: $17.6 billion (-17%)

YTD Earnings: $2.5 billion (-52%)

Comments: U.S. sales decreased 38% to $2.2 billion in the quarter due to patent expirations for Avapro/Avalide in March 2012 and Plavix in May 2012. International sales were up 6% to $2.0 billion. Plavix sales were down 97% to $49 million. Avapro/Avalide sales were down 57% to $84 million. Abilify sales were up 11% to $819 million. Sprycel sales were up 24% to $281 million. Yervoy sales were up 47% to $211 million. Orencia sales were up 26% to $325 million. Onglyza/Kombiglyze sales were $198 million, up 29%. R&D expenses increased 7% to $1.1 billion in the quarter.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On